Is Danyelza Approved for High-Risk Neuroblastoma?
Yes, Danyelza (naxitamab-gqgk) is FDA-approved to treat high-risk neuroblastoma in children and adults. It targets relapsed or refractory cases after prior therapy, including anti-GD2 therapy. Approval came in November 2020 for patients aged 1 year and older with bone or bone marrow involvement.[1][2]
How Does Danyelza Work Against Neuroblastoma?
Danyelza is a monoclonal antibody that binds GD2, a protein on neuroblastoma cells, marking them for immune destruction. It combines with GM-CSF to boost white blood cell activity. Clinical trials showed 50 out of 97 patients had stable disease or better response, with 23 achieving complete or partial remission.[1]
What Do Clinical Trial Results Show for High-Risk Cases?
In the phase 2 Naxitamab Compassionate Use trial, patients with high-risk neuroblastoma (often stage 4 with MYCN amplification) responded despite heavy prior treatments. Median progression-free survival reached 6.7 months, and overall survival was 23.3 months. Bone marrow responses occurred in 63% of cases.[2][3]
Who Qualifies for Danyelza Treatment?
Treatment fits pediatric and adult patients with:
- Relapsed/refractory high-risk neuroblastoma.
- Detectable bone marrow disease via standard tests.
- Prior anti-GD2 therapy like dinutuximab.
Administered intravenously every 4 weeks in cycles, with premedication for side effects.[1]
What Side Effects Do Patients Experience?
Common issues include pain (hypersensitivity reactions), nausea, low blood pressure, and fever. Infusion reactions hit 93% of patients, often managed with drugs like acetaminophen. Serious risks: capillary leak syndrome (18%) and hemorrhage (12%). Monitoring in clinical settings is required.[1][2]
How Does Danyelza Compare to Unituxin?
Both target GD2 for high-risk neuroblastoma, but Danyelza is for relapsed cases post-Unituxin (dinutuximab). Unituxin suits frontline maintenance; Danyelza offers later-line options with better bone marrow clearance in trials. No head-to-head studies exist.[3]
Ongoing Trials and Future Access
Phase 3 trials (e.g., NCT03373097) test Danyelza with irinotecan/gm-CSF for first relapse. EU approval came in 2022. Patent protection via Y-mAbs Therapeutics lasts until around 2035, with no listed generics on DrugPatentWatch.com.[4][1]
[1]: FDA Label - Danyelza (naxitamab-gqgk), https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171s000lbl.pdf
[2]: Memorial Sloan Kettering trial data, https://www.mskcc.org/cancer-care/types/neuroblastoma/treatment/danyelza
[3]: NEJM study on naxitamab, https://www.nejm.org/doi/full/10.1056/NEJMoa1916025
[4]: DrugPatentWatch.com - Naxitamab patents, https://www.drugpatentwatch.com/p/tradename/DANYELZA